Akebia Therapeutics Obtains $1,500,000 New Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=2d96a712-0235-4a16-8bdd-ff9ebd9343dd
Date
7/3/2014
Company Name
Akebia Therapeutics
Mailing Address
245 First Street Cambridge, MA 02142 USA
Company Description
Akebia Therapeutics (NASDAQ: AKBA) is a pharmaceutical company with a focus on treatments for ischemia and improvement of vascular disease.
Website
http://www.akebia.com
Transaction Type
Venture Equity
Transaction Amount
$1,500,000
Transaction Round
Undisclosed
Proceeds Purposes
The company intends to use the capital to fund clinical development of HT-100 (delayed-release halofuginone), an orally available, small molecule drug candidate intended to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with DMD.
M&A Terms
Venture Investor
Venture Investor